Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for RESLIZUMAB
- Reslizumab in Patients With Severe Asthma Who Failed to Respond to Omalizumab
- A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
- Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study
- An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation
- Effect of Reslizumab in Chronic Rhinosinusitis
- Effects of Mepolizumab Compared to Placebo on Airway Physiology in Patients With Eosinophilic Asthma: MEMORY Study
- Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosinophilic Asthma
- An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils
- Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
- Cross-sectional Study for Identification and Description of Severe Asthma Patients
- Absolute Bioavailability of Reslizumab in Healthy Subjects
- Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma
- Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma
- A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
- A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma
- A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma
- Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis
- Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis
Clinical trials list
click for details